Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hospital-Based Infections

This article was originally published in Start Up

Executive Summary

Physicians and hospitals are concerned about the problem of hospital-acquired infections, as is the US Centers for Disease Control, which has launched a campaign to prevent antimicrobial resistance in health care settings. Start-ups believe they can help, with effective and rapid tests for infectious disease and narrow spectrum antimicrobials targeted to specific pathogens. buhed ehnwhihOntros sion, acarel

You may also be interested in...

Infectio Diagnostic Inc.

Current microbial diagnostics take two to three days to identify infectious agents. During that time, patients in hospitals might not receive the appropriate treatment, or might infect others with antibiotic-resistant microbes. Infectio Diagnostic is developing a rapid DNA diagnostic that will be able to identify infecious microbes in under an hour.

Entomed SA

"Insects represent three times the biodiversity of plants and microorganisms put together, " says Mario Thomas, PhD, CEO of Entomed SA. That's why Entomed is hopeful that insect genes will help it discover novel anti-infectives and other drugs.

Microbia Inc.

Microbia Inc. has amassed a large patent portfolio covering novel targets for rendering fungi harmless, disrupting communities of bacteria, and for harnessing these organisms to the task of manufacturing useful products. Well-armed with $59 million in funding and the chemistry skills to turn biological insights into weapons against infectious diseases, Microbia hopes to create new antimicrobial drugs that work in fundamentally different ways than the drugs that are available today.

Related Content

Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts